THE ENDOMETRIUM AS A TARGET ORGAN IN POSTMENOPAUSAL WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Postmenopausal women are at risk for different endometrial abnormalities in the presence of involutional changes in the reproductive system and features of the somatic status. 40-60% of women receiving low-dose and microdose menopausal hormone therapy may notice vaginal bleeding of various intensities, which is not organic and, on the one hand, results in discontinuation of therapy and a reduction in its adherence, and, on the other, in psychological impairment. The literature review presents data from randomized controlled studies analyzing the minimally effective and safe dose of menopausal hormone therapy and its impact on the endometrium. Literature was searched for in Russian (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full-text articles published in 2014 to 2020.

Full Text

Restricted Access

About the authors

Elena N. ANDREEVA

National Medical Research Center of Endocrinology, Ministry of Health of Russia; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: endogin@mail.ru
MD, professor of the cathedra of Reproductive medicine and Surgery of A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Russian Ministry of Health, the Leader of the Endocrinological Gynecology Department of the Endocrinology Research Centre of the Russian Ministry of Health Moscow, Russia

Ekaterina V. SHEREMETYEVA

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: sl98lk@yandex.ru
MD, PhD, lead employee of the Endocrinological Gynecology Department Moscow, Russia

Olga R. GRIGORYAN

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: icebergl995@mail.ru
MD, Professor, main research worker of the Endocrinological Gynecology Department Moscow, Russia

Robert K. MIKHEEV

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: icebergl995@mail.ru
medical student Moscow, Russia

Yulia S. ABSATAROVA

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: korsil2008@ya.ru
MD, PhD, researcher of the Endocrinological Gynecology Department Moscow, Russia

References

  1. Адамян Л.В., Мельникова Н.С., Зайратьянц О.В., Балицкий Е.В., Кортукова Р.А., Козлова О.В. Патология эндометрия в пожилом и старческом возрасте (скрининговое исследование). Архив патологии. 2013; 75(6): 32-8.
  2. Globocan 2012. Cancer Incidence and Mortality Worldwide: IARC Cancer Base № 11. Lyon, France: IARC; 2013. Accessed January 30, 2018. Available at: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012
  3. Аксель Е.М. Заболеваемость и смертность от злокачественных новообразований органов женской репродуктивной системы в России. Онкогинекология. 2015; 1: 4-13.
  4. Адамян Л.В., Мельникова Н.С., Касян В.Н. Патология эндометрия в постменопаузе: нужен ли ультразвуковой скрининг? Проблемы репродукции. 2019; 25(2): 113-9. https://dx.doi.org/10.17116/repro201925021113.
  5. Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., Sessa C.; ESMO Guidelines Working Group. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(6): 33-8. https://dx.doi.org/10.1093/annonc/mdt353.
  6. Lortet-Tieulent J., Ferlay J., Bray F., Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J. Natl. Cancer Inst. 2018; 110(4): 354-61. https://dx.doi.org/10.1093/jnci/djx214.
  7. Гасанова С.Х. Низкодозированная гормонотерапия в постменопаузе - состояние эндометрия и маточного кровотока: авто-реф. дисс.. канд. мед. наук. М.; 2007. 26 с.
  8. Compel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Review. Climacteric. 2018; 21(4): 321-5.
  9. Pal N., Broaddus R.R., Urbauer D.L., Balakrishnan N., Milbourne A., Schmeler А. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet. Gynecol. 2018; 131: 109-16.
  10. Макаров О.В., Сергеев П.В., Карева Е.Н. Гиперпластические процессы эндометрия: диагностика и лечение с учетом рецепторного профиля эндометрия. Акушерство и гинекология. 2003; 3: 32-6.
  11. Shanthala S., Subramanya H. Immunohistochemical study of hormonal receptors in endometrium of women with dysfunctional uterine bleeding: a two year experience of a tertiary care center. Arch. Med. 2018; 10(6). https://dx.doi. org/10.21767/1989-5216.1000289.
  12. Bircan S., Ensari A., Ozturk S., Erdogan N., Dundar I., Ortac F. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol. Oncol. Res. 2005; 11(1): 32-9.
  13. Hu K., Zhong C., He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer. 2005; 15(3): 537-41.
  14. Hapangama D., Kamal A., Bulmer J. Estrogen receptor ß: the guardian of the endometrium. Hum. Reprod. Update. 2014; 21(2): 174-93. https:// dx.doi.org/10.1093/humupd/dmu053.
  15. Бреусенко В.Г., Карева Е.Н., Голухов Г.Н., Ивановская Т.Н., Голова Ю.А., Коцюбинская Н.А., Бехбудова Л.Х., Степанов К.И., Воробьева Г.Ю. Пролиферативные процессы в эндометрии у пациенток в пре- и постменопаузе. Влияние патологической пролиферации на стероидно-рецепторный профиль эндометрия. Российский вестник акушера-гинеколога. 2016; 16(4): 25-31. https://dx.doi.org/10.17116/rosakush201616425-31.
  16. Teresinski L., Sipak O., Ryb A., Masiuk M., Rotter I., Ratajczak W.et al. Assessment of morphological changes and steroid receptors in the uteri of postmenopausal women. Histol. Histopathol. 2019; 34(6): 631-44. https:// dx.doi.org/10.14670/HH-18-063.
  17. Carugno J. Clinical management ofvaginal bleeding in postmenopausal women 2020. Climacteric. 2020; Apr 1: 1-7. https://dx.doi.org/10.1080/13697137.202 0.1739642.
  18. Begum J., Samal R. A clinicopathological evaluation of postmenopausal bleeding and its correlation with risk factors for developing endometrial hyperplasia and cancer: A Hospital-Based Prospective Study. J. Midlife Health. 2019; 10(4): 179-83. https://dx.doi.org/10.4103/jmh.JMH_136_18.
  19. Burbos N., Musonda P., Duncan T.J., Crocker S.C., Nieto J.J., Morris E.P. Postmenopausal vaginal bleeding in women using hormone replacement therapy. Menopause Int. 2012; 18: 5-9.
  20. Clarke M.A., Long B.J., Sherman M.E., Lemens M.A., Podratz K.C., Hopkins M.R. et al. A prospective clinical cohort study of women at increased risk for endometrial cancer. Gynecol. Oncol. 2020; 156(1): 169-77. https:// dx.doi.org/10.1016/j.ygyno.2019.09.014.
  21. Choubara A., Sundar S., Ewies A.A. Predictors of malignancy in endometrial polyps: study of 421 women with postmenopausal bleeding. Climacteric. 2018; 21: 82-7.
  22. Lee S.C., Kaunitz A.M., Sanchez-Ramos L., Rhatigan R.M. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet. Gynecol. 2010; 116: 1197-205.
  23. Trabert B., Wentzensen N., Yang H.P., Sherman M.E., Hollenbeck A.R., Park Y., Brinton L.A. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer. 2013; 132(2): 417-26. https:// dx.doi.org/10.1002/ijc.27623.
  24. Hein A., Schneider M.O., Renner S.K., Fasching P.A., Fiessler C., Titz S. et al. Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Arch. Gynecol. Obstet. 2020; 301(1): 289-94. https://dx.doi.org/10.1007/s00404-019-05414-3.
  25. Di Donato V., Palaia I., DAniello D., Musacchio L., Santangelo C., Di Mauro F. et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review. Oncology. 2020; 98(4): 195-201. https:// dx.doi.org/10.1159/000505427.
  26. Rotenberg O., Fridman D., Doulaveris C., Renz M., Kaplan J., Cebb J. et al. Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. Ultrasound Obstet. Gynecol. 2020; 55(4): 546-51. https://dx.doi.org/10.1002/uog.20421.
  27. Luo J., Hendryx M., Manson J.E., Figueiredo J.C., LeBlanc E.S., Barrington W. et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019; 3(4): pkz054. https://dx.doi.org/10.1093/jncics/pkz054.
  28. LegaI.C., LipscombeL.L. Review: Diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr. Rev. 2020; 41(1). pii: bnz014. https://dx.doi. org/10.1210/endrev/bnz014.
  29. Walsh D.M., Hokenstad A.N., Chen J., Sung J., Jenkins C.D., Chia N. et al. Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Sci. Rep. 2019; 9(1): 19213. https://dx.doi. org/10.1038/s41598-019-55720-8.
  30. Sturdee D.W., Pines A.; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-20. https:// dx.doi.org/10.3109/13697137.2011.570590.
  31. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19: 257-71. https://dx.doi.org/10.1097/gme.0b013e31824b970a.
  32. Gerlinger C., Gude K., Schmelter T., Schaefers M., Endrikat J. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric. 2015; 18(4): 512-7. https://dx.doi.org/10.3109/13697137.2015.! 036855.
  33. Archer D.E., Thorneycroft I.H., Foegh M. et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005; 12: 716-27. https://dx.doi.org/10.1097/01. gme.0000177318.24005.b1.
  34. Григорян О.Р. Эффективность и безопасность использования ультранизких доз дроспиренона и 17Р-эстрадиола у женщин в постменопаузе. Мета-анализ. Медицинский ответ. 2018; 7: 126-32. https:// dx.doi.org/10.21518/2079-701X-2018-7-126-132.
  35. Sitruk- Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005; 8: 4-12. https:// dx.doi.org/10.1080/13697130500330382.
  36. Mueck A.O., Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2005; 3: 45-54. https://dx.doi.org/10.2174/1568016052773270.
  37. Genazzani A.R., Schmelter T., Schaefers M., Gerlinger C., Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17ß -estradiol in postmenopausal women. Climacteric. 2013; 16: 490-8. https://dx.doi.org/10.3109/13697137.2013.783797.
  38. Gerlinger C., Gude K., Alincic-Kunz S., Schafers M. Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. Climacteric. 2012; 15: 52-8. https://dx.doi.org/10.3109/13697137.2011.587055.
  39. Kurman R.J., Hedrick Ellenson L., Ronnett B.M. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. https://dx.doi. org/10.1007/978-3-319-46334-6.
  40. Hunter M.S. The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of their emotional and physical health. Psychol. Health. 1992; 7: 45-54. https://dx.doi.org/10.1186/1477-7525-1-41.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies